RDEA Ardea Biosciences, Inc. (MM)

DALLAS, May 1, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP announce an investigation into alleged violations of shareholder protection laws by officers and directors of Ardea Biosciences, Inc. (NASDAQ: RDEA) in connection with a buyout agreement for $32.00 per share to AstraZeneca. Concerned RDEA investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies.

"In our investigation for stockholders, we critically assess whether the board has adequately shopped the company to maximize the best deal for investors and whether they are disclosing all material benefits and costs," said Hamilton Lindley. "Our proposed investor class action seeks to ensure that RDEA shareholders' interests are protected in accordance to the board of directors' fiduciary duties."

Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. RDEA stockholders – or anyone with knowledge about this acquisition – should contact lawyer Hamilton Lindley at hlindley@goldfarbllp.com or 877-583-2855 with questions or concerns.

Hamilton Lindley

Goldfarb LLP

2501 N. Harwood, Ste. 1801

Dallas, TX 75201

(877) 583-2855 Toll Free Telephone

(214) 583-2233 Local Phone Number

(214) 583-2234 Fax Number

www.goldfarbllp.com

SOURCE Goldfarb LLP